Navigation Links
Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
Date:11/17/2010

RICHMOND, Calif., Nov. 17, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS. The data from study SB-509-801 demonstrated that the drug was well-tolerated in subjects with ALS and that 40% of SB-509 treated subjects had delayed deterioration of toe and ankle muscle strength as measured by manual muscle testing (MMT) compared to 23% of baseline-matched historic controls.  In addition, positive improvements in electrophysiological measures of motor nerves were observed in a subset of treated subjects.  The data were presented at the Society for Neuroscience Annual Meeting which is being held in San Diego.  

"These data are consistent with the delay in muscle deterioration that we have observed in both preclinical models of ALS as well as in clinical studies of this drug in subjects with diabetic neuropathy, a condition that is also characterized by degeneration and deterioration of nerve function," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our primary aim in this trial was to assess safety and tolerability of treatment with SB-509 in this vulnerable patient population and to conduct a signal-seeking study in which we assessed the effect of treatment on several clinical measures of function in ALS.  As this was an early-stage trial, for safety reasons we treated subjects twice over a 90 day period, although our positive preclinical animal data were achieved with a more frequent dosing schedule.  With that said, the delayed deterioration in muscle strength in the ankle and toe are very encouraging and may reflect the importa
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
3. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
4. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
7. Sangamo Announces Closing of Common Stock Offering
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
(Date:8/27/2014)... Decision Resources Group finds that the intense ... health system and hospital sector in recent ... Methodist Le Bonheur Healthcare and Baptist Memorial Health Care ... care. In addition, a national contract recently signed between ... enrollment in the Memphis market, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... Tejal K. Gandhi, MD, MPH, CPPS, president ... the NPSF Lucian Leape Institute, is among the 100 Most ... of Modern Healthcare magazine. Also on the list are NPSF ... MBA; NPSF Lucian Leape Institute members Carolyn Clancy, MD; ... member of both the Institute and the NPSF Board of ...
(Date:8/27/2014)... 27, 2014 CarePoint Health is ... Hoboken Pediatrics has joined our network, CarePoint Health ... Dr. Piotr Oko, Dr. Yanina Meshko and Dr. ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Driven by ... weatherstrip is expected to grow steadily during the next ... to reach 1.381 billion meters by end-2017. Tightness is ... seals are one of the most-used parts in an ... seals stood at 995 million meters, up just under ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... 27, 2014) Not all students returning to school ... vaccinations. A new study conducted by Jennifer Reich, a ... the reasons why children may not be fully vaccinated ... According to the National Network for Immunization Information, three ... any vaccines, with almost half of all children receiving ...
Breaking Medicine News(10 mins):Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Automobile Weatherstrip Sector in China Analysed in New SinoMarketInsight Research Study Published at MarketPublishers.com 2Health News:Automobile Weatherstrip Sector in China Analysed in New SinoMarketInsight Research Study Published at MarketPublishers.com 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Expression of privilege in vaccine refusal 2
... On Thursday, January 8, Rhode Island Hospital treated ... as NanoKnife. Damian Dupuy, MD, director of ablation services ... ablation treatment, performed the procedure -- the first time ... the United States. , NanoKnife is an image-guided device ...
... Protica, Inc., the makers of the first capsulized ... to its product line. Following the FDA approval ... made with the natural sweetener will hit the ... the compact 2.9 fluid ounce beverage utilizes Actinase(R). ...
... Ill. and BATESVILLE, Ind., Jan. 9 ,Recognizing the ... excellent care at the patient,s bedside, Joint Commission,Resources ... are collaborating to launch a Nurse,Safety Scholar-in-Residence program ... Joint Commission. Hill-Rom is a global medical technology ...
... perception, reality , , FRIDAY, Jan. 9 (HealthDay News) -- ... their child,s eating and exercise habits, a new study ... Journal of Nutrition Education and Behavior that ... exercised well, while those with older children did not. ...
... Two words strike fear in the hearts of men and ... through the shock of that diagnosis, suffered the grief and ... the opportunity of a lifetime. In his new book, "Life ... AuthorHouse -- http://www.authorhouse.com ), he provides a valuable roadmap ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... January 7, 2009 related to a proposed transaction with ... the outstanding shares,of the Seller. , ...
Cached Medicine News:Health News:Rhode Island Hospital first in US to treat kidney tumor with new device using electrical pulses 2Health News:Protica Launches All-Natural Protein Beverage, Proasis 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Mach One Corporation Enters Letter of Intent to Acquire Ceres Organic Harvest, Inc. 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: